Scientists today agree that there are five molecules that are known to affect or cause Alzheimer's disease, which plagues an estimated five million Americans. The potency of these molecules is linked to environmental factors such as diet and lifestyle.
Scientists have developed new synthetic molecules as models to study the structural and functional role of the proline residue and tetrapeptide sequence important for the regulation of cancer cell apoptosis by the XIAP protein.
Recently published findings present possible new opportunities for developing organism-specific drugs, which target the pathogen that causes tuberculosis but leave other microorganisms, which are beneficial to us, untouched.
Ligand Pharmaceuticals Inc. reported a smaller fourth-quarter profit compared to a year ago, when one-time payments boosted its revenue. Ligand said its net income fell to $2.4 million.
A new study suggests a way to help men with early, low-risk prostate cancer avoid being overtreated for a disease that in most cases will never threaten their lives. It found that a drug can slow the growth of these tumors in men who opt to be monitored instead of having treatment right away.
A unit of Johnson & Johnson has recalled 70,000 syringes of its antipsychotic drug Invega Sustenna after finding that some of the pre-filled syringes may have cracks which possibly could affect the drug's sterility.
Novo Nordisk A/S says it has been subpoenaed by the U.S. Attorney for the District of Massachusetts in an investigation of how the Danish pharmaceutical company markets three diabetes drugs.
French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the market in lucrative drugs for rare genetic disorders.
The development of monoclonal antibodies as therapies and as diagnostics has made tremendous advances since the approval of the first therapeutic mAb 25 years ago. New technologies have enabled the synthesis of fully human mAbs.
Affymetrix, Inc. launched its Anatrace brand Neopentyl Glycol Class Detergents, the next generation of detergents to significantly advance the study of integral membrane proteins, the most important proteins found in the human genome.
Tecan and SciRobotics announced the launch of the integrated Pickolo colony-picker for the Freedom EVO liquid handling platforms, providing customers with a complete solution for automation of molecular biology workflows, from cloning to PCR sequencing or cell-based screening.
BioConvergence and Creapharm have combined their strengths to offer the biotech and pharmaceutical industries experienced talent and a variety of services required during preclinical and early stage clinical phases.
Jomaa Pharma GmbH and Medicines for Malaria Venture announced that they have signed a Memorandum of Understanding for the joint development of fosmidomycin, as a component of non-artemisinin based combination therapy, for acute Plasmodium falciparum malaria.
Gilead Sciences, Inc. announced that it has refiled a New Drug Application with the U.S. Food and Drug Administration for the single-tablet regimen of Truvada and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 for HIV-1 infection in adults.
Mylan Inc. said it started selling a generic version of Pfizer Inc.'s antifungal drug Vfend. The Pittsburgh drugmaker is now selling Vfend, or voriconazole, in tablets of 50 milligrams and 200 milligrams.